Radar · Neurology in Ile de France
Best Neurology Companies in Ile de France, France
The 45 best Neurology companies in Ile de France, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ethypharm.
By Rohit KhannaTrends & Stories
45companies tracked
$904.3Mdisclosed funding
0unicorns
28have raised
FLIAR INTELLIGENCE · NEUROLOGY × ILE DE FRANCE
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
120kcombined LinkedIn audience
79%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Neurology companies in Ile de France
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Ethypharm Developer of therapies for the treatment of pain and addiction | $248M | 32 mo ago | 1,500 | Aurore Gérigné Co-founder & VP | WordPressApple iCloud MailMySQL+15 | 729 patents Patents concentrated in health & consumer products | — |
| 2 | Syremis Developer of novel medicines for mental health conditions 22Funding top 20%Global top 45%Talent bottom 49%Tech bottom 29% All 5 signals ▾Fundingtop 20% Globaltop 45% Talentbottom 49% Techbottom 29% Marketbottom 25% Funding: Raised $165M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 3 countries beyond France rank vs industry peers · Fliar Intelligence Index 22/100 | $165M | 8 mo ago | — | Elisabeth Kogan Co-Founder & CEO | WordPressMySQLPHP+15 | — | — |
| 3 | BioSerenity Provider of smart healthcare solutions for sleep and EEG lab management 60Moat top 19%Tech top 25%Patents top 29%Innovation top 34% All 11 signals ▾Moattop 19% Techtop 25% Patentstop 29% Innovationtop 34% Fundingtop 34% Markettop 45% Growthtop 45% Producttop 46% Newsbottom 43% Globalbottom 42% Fin. healthbottom 36% Moat: Editorial + unicorn rating 8/10 · IP moat: 140 patents Tech: 53 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront rank vs industry peers · Fliar Intelligence Index 60/100 | $121M | 33 mo ago | 340 | — | WordPressApple iCloud MailMicrosoft 365+24 | 140 patents Wearable EEG and textile electrode systems for continuous physiological monitoring. | — |
| 4 | AB Science Developer of tyrosine kinase inhibitors for multiple disease indications 42Funding top 20%Patents top 21%Innovation top 28%Moat top 28% All 9 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 28% Moattop 28% Newstop 33% Growthtop 45% Techbottom 41% Globalbottom 38% Marketbottom 21% Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $83M | 3 mo ago | 3 | — | WordPressPleskMySQL+22 | 454 patents Small‑molecule kinase and tubulin inhibitors for hematologic cancers and neurodegenerative disorders | — |
| 5 | MedDay Pharmaceuticals Developer of therapeutics for the treatment of neurological and psychiatric diseases | $49M | 124 mo ago | 82 | — | — | 58 patents Patents concentrated in health & consumer products | — |
| 6 | Coave Therapeutics Developer of gene therapy for ocular and neurological disease 50Funding top 33%Patents top 34%Growth top 35%Moat top 36% All 9 signals ▾Fundingtop 33% Patentstop 34% Growthtop 35% Moattop 36% Innovationtop 42% Talentbottom 49% Techbottom 44% Globalbottom 43% Marketbottom 38% Funding: Raised $44.0M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Patents: 27 patents matched (strict assignee match) · 26 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 19 mo ago | 34 | Rodolphe Clerval Chief Executive Officer | WordPressApple iCloud MailMicrosoft 365+23 | 27 patents Engineered AAV viral vectors with lactam/squaramide modifications for CNS gene therapy | — |
| 7 | AlgoTx Developer of therapeutic solutions for pain management | $39M | 41 mo ago | 10 | Olivier Bohuon Founder | — | — | — |
| 8 | Acticor Biotech Developing immunotherapeutics for treating ischemic stroke | $31M | 81 mo ago | 29 | Gilles Avenard CEO | Webflow EcommerceWebflowApple iCloud Mail+13 | 58 patents Anti‑GPVI antibody therapeutics for cardiovascular disease and platelet aggregation inhibition | — |
| 9 | Robeauté Developer of microrobots for neurosurgical applications 35Growth top 35%Talent top 38%Funding top 44%Global bottom 39% All 6 signals ▾Growthtop 35% Talenttop 38% Fundingtop 44% Globalbottom 39% Techbottom 38% Marketbottom 27% Growth: Fresh capital in last 24 mo Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 19 mo ago | 15 | Joana Cartocci Co-Founder & COO | WebflowApple iCloud MailMicrosoft 365+8 | — | — |
| 10 | Pharnext Developer of therapeutics for the treatment of neurological diseases | $23M | 77 mo ago | 109 | Daniel Cohen Founder | — | 630 patents Combinatorial drug formulations for neurodegenerative disorders, especially CMT and Alzheimer disease | — |
| 11 | EG 427 Developer of gene therapies for neurogenic bladder 35Talent top 28%Patents top 37%Funding top 38%Moat top 39% All 9 signals ▾Talenttop 28% Patentstop 37% Fundingtop 38% Moattop 39% Innovationtop 48% Globalbottom 43% Marketbottom 33% Techbottom 33% Newsbottom 20% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Patents: 17 patents matched (strict assignee match) · 17 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 35/100 | $20M | 18 mo ago | 17 | Pierre Denys Co-Founder | PleskPHPYouTube+11 | 17 patents Herpes simplex virus gene‑therapy vectors for bladder and brain therapeutic applications | — |
| 12 | Pharmaleads Mid-clinical stage biopharma company developing small molecule therapeutics for chronic pain conditions | $14M | 146 mo ago | 10 | Dominique Bouvier CEO | — | 198 patents Synthesis of peptide‑based neprilysin/APN inhibitors for ocular and neuropathic pain. | — |
| 13 | MITEM Pharma Developer of targeted therapies to treat multiple diseases | $11M | 52 mo ago | — | Eric Thierry Co-Founder & COO | — | — | — |
| 14 | Rest Therapeutics Developer of therapeutics for the treatment of neurological and psychiatric disorders | $5M | 27 mo ago | 6 | Gilles Rubinstenn Founder & CEO | — | 19 patents Neuroprotective drug compounds targeting NMDA receptors and acetylcholinesterase inhibition. | — |
| 15 | ORPHELIA Pharma Developer of therapies for treating pediatric neurology, pediatric oncology, and hematology | $4M | 80 mo ago | 9 | Hugues Bienayme Founder & CEO | — | — | — |
| 16 | Julier Medical Developer of a medical device to treat acute ischemic stroke | $3M | 43 mo ago | 4 | Laurent Grandidier Co-Founder | — | — | — |
| 17 | BrainEver Developer of drug candidates to treat neurodegenerative diseases | $3M | 50 mo ago | 17 | Bernard Gilly Co-Founder & CEO | — | 4 patents Formulation technologies for stabilized therapeutic proteins and peptides | — |
| 18 | Op2Lysis Provider of drugs for treating neurology diseases | $3M | 49 mo ago | 9 | Christophe Gaudin Co-Founder | — | 7 patents Sustained‑release thrombolytic drug formulations for treating clotting and bleeding disorders. | — |
| 19 | Biophytis Developer of drugs for neuromuscular and age-related diseases 45Patents top 32%Moat top 35%Funding top 37%Innovation top 38% All 10 signals ▾Patentstop 32% Moattop 35% Fundingtop 37% Innovationtop 38% Globaltop 45% Partnerstop 45% Newstop 46% Growthbottom 47% Techbottom 43% Marketbottom 42% Patents: 175 patents matched (strict assignee match) · 62 filings since 2022 vs 105 in 2017-21 Moat: Editorial + unicorn rating 5/10 · IP moat: 175 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $3M | 5 mo ago | 24 | — | WordPressPleskMySQL+21 | 175 patents Phytoecdysteroid-based therapeutics for muscle atrophy, SMA, obesity, viral respiratory, ocular diseases | 1 expansion |
| 20 | Mensia Technologies A non-invasive device for the treatment of ADHD | $2M | 83 mo ago | 20 | Michel du Peloux CEO | — | — | — |
| 21 | InBrain Pharma Developer of therapeutic solutions for the treatment of neurodegenerative diseases | $1M | 15 mo ago | 4 | Matthieu Fisichella Co-Founder & CEO | — | — | — |
| 22 | Brain Vectis Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease | $1M | 119 mo ago | 5 | — | — | — | — |
| 23 | Neurallys Developing a device for the treatment of Hydrocephalus | $847K | 88 mo ago | 3 | Philippe Auvray Co-Founder & CEO | — | 11 patents CSF turbidity measurement and ventriculoperitoneal shunt malfunction detection medical devices | — |
| 24 | Mapreg Developer of drug to treat neuronal pathologies | $505K | 191 mo ago | 10 | Koichi Murakami Founder | — | 33 patents Neurosteroid drug compounds for depression and substance‑use disorder therapies | — |
| 25 | Suricog Provider of eye-tracking solutions for diagnosis and monitoring of neurological disorders | $484K | 139 mo ago | — | Marc Massonneau Co-Founder & Owner & CEO | — | 25 patents Eye‑tracking and ophthalmic measurement systems for diagnosing ocular and facial parameters. | — |
| 26 | NeoNeuro Provider of aptamer-based molecular diagnostics for Alzheimer's Disease | $363K | 71 mo ago | — | Gregory Penner Founder & President | — | 6 patents Aptamer-based biomarker detection for early-stage Alzheimer's disease diagnostics | — |
| 27 | Alzohis Non-invasive diagnostics for neurodegenerative diseases | $110K | 76 mo ago | 5 | Myriam Taverna Co-Founder & CSO | — | 10 patents AI-based differential diagnosis tools for neurodegenerative diseases | — |
Top 12 Neurology companies in Ile de France
#1
Public · Paris, Ile de France · founded 2001 · 3 employees$83.2Mraised▾
Public · Paris, Ile de France · founded 2001 · 3 employees
Developer of tyrosine kinase inhibitors for multiple disease indications. The company's lead candidate drugs are masitinib, a highly selective tyrosine kinase inhibitor, and AB8939, a new generation microtubule destabilizer for oncology, neurodegenerative and inflammatory indications.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 28%Moat
top 28%News
top 33%Growth
top 45%Funding: Raised $83.2M across 9 rounds · 9 rounds over 9 yrs (1.0/yr) · Last round Post IPO (May 2026)
Patents: 461 patents matched (strict assignee match) · 78 filings since 2022 vs 86 in 2017-21 · Latest publication 2025
Innovation: 461 patents (top 5% of patent-holders) · 78 filings since 2022 vs 86 in 2017-21
Funding rounds
- May 2026Post IPO$3M
- Oct 2025Post IPO$3.3M
- Jul 2025Post IPO$2.3M
- May 2025Post IPO$2M
Tech stack
Contact Form 7Core-JsGoogle AnalyticsGoogle Font ApiGsapIsotope
#2
Series A · Paris, Ile de France · founded 2017$165Mraised▾
Series A · Paris, Ile de France · founded 2017
Developer of novel medicines for mental health conditions. The company focuses on neuropsychiatric treatments rooted in clinically validated mechanisms. It advances programs for schizophrenia, psychotic disorders, major depressive disorder, and bipolar depression. The lead program is a dual agonist in Phase 1 development. Another program is a novel antagonist currently in IND-enabling studies.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 20%Global
top 45%Talent
bottom 49%Tech
bottom 29%Market
bottom 25%Funding: Raised $165M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (Dec 2025)
Global: Investors from 3 countries beyond France
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers — 2.1% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum -2 · hiring: Chemistry Lead (R&D), CMCL Lead
Funding rounds
- Dec 2025Series A$165M
Founders & team
Investors
Dexcel, Third Rock Ventures, Bain Capital Life Sciences, Google Ventures, QVT Family Office, Pictet Group
Tech stack
Core-JsElementorGoogle Font ApiHello ElementorJqueryJquery Migrate
#3
Public · Romainville, Ile de France · founded 2006 · 24 employees$2.6Mraised▾
Public · Romainville, Ile de France · founded 2006 · 24 employees
Developer of drugs for neuromuscular and age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Other drug candidate, Macuneos (BIO201) for the treatment of retinal diseases, including dry AMD and Stargardt disease.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Patents
top 32%Moat
top 35%Funding
top 37%Innovation
top 38%Global
top 45%Partners
top 45%Patents: 175 patents matched (strict assignee match) · 62 filings since 2022 vs 105 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 5/10 · IP moat: 175 patents · 10 curated direct competitors tracked
Funding: Raised $2.6M across 6 rounds · 6 rounds over 14 yrs (0.4/yr) · Last round Post IPO (Mar 2026)
Audience (LinkedIn): 5k LinkedIn followers — 4.2% of this cohort's audience
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Mar 2026Post IPO$1.6M
- Jun 2021Post IPO$38.2M
- Jul 2020Post IPO$6.9M
- Oct 2017Post IPO$12.3M
Investors
Seventure Partners, CM-CIC Capital Prive, Kreos Capital
Tech stack
Apple Icloud MailCore-JsElementorGoogle AnalyticsGsapIsotope
#4
Series B · Paris, Ile de France · founded 2014 · 34 employees$44Mraised▾
Series B · Paris, Ile de France · founded 2014 · 34 employees
Developer of gene therapy for ocular and neurological disease. The drug candidates include CTx-PDE6b for inherited retinal dystrophy, CTx-ABCA4 for Stargardt’s Disease, CTx-GBA1 for Parkinson’s, and neuronopathic Gaucher diseases. These drugs are based on the AAV-ligand conjugates platform for targeted delivery.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 33%Patents
top 34%Growth
top 35%Moat
top 36%Innovation
top 42%Talent
bottom 49%Funding: Raised $44.0M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) · Last round Series B (Jan 2025)
Patents: 27 patents matched (strict assignee match) · 26 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 7k LinkedIn followers — 5.9% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Jan 2025Series B$33M
- Jul 2021Series B$39M
- Jul 2016Series A$4.4M
- Jul 2015Grant (prize money)$166.6K
Founders & team
Investors
Omnes Capital, Sham, GO CAPITAL, Ministry of Higher Education and Research, Seroba Life Sciences, Thea Open Innovation
Tech stack
Apple Icloud MailChart.JsComplianzContact Form 7Font AwesomeGoogle Font Api
#5
Series B · Paris, Ile de France · founded 2020 · 17 employees$20Mraised▾
Series B · Paris, Ile de France · founded 2020 · 17 employees
Developer of gene therapies for neurogenic bladder. The company has an HSV-1 vector platform for the delivery and expression of a transgene encoding the light chain of botulinum toxin F in sensory neurons to treat neurogenic bladder after spinal cord injury, overactive bladder, and Interstitial cystitis.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 28%Patents
top 37%Funding
top 38%Moat
top 39%Innovation
top 48%Global
bottom 43%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Patents: 17 patents matched (strict assignee match) · 17 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding: Raised $20.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series B (Feb 2025)
Audience (LinkedIn): 3k LinkedIn followers — 2.3% of this cohort's audience
Funding rounds
- Feb 2025Series B$28.2M
- Jul 2023Series A$20M
Founders & team
Investors
Andera Partners, Bpifrance, SCI Ventures
Tech stack
Alpine.JsCloudflareCloudflare Browser InsightsGoogle Font ApiHttp/3Jsdelivr
#6
Seed · Paris, Ile de France · founded 2017 · 15 employees$28Mraised▾
Seed · Paris, Ile de France · founded 2017 · 15 employees
Developer of microrobots for neurosurgical applications. The platform utilizes miniature robots to diagnose, treat, and monitor brain diseases with high precision. It aims to improve patient outcomes and advance the field of neurosurgery and for the treatment of various brain-related disorders. It is used for tasks like biopsies, drug delivery, electrode implantation, and real‑time data collection through complex 3D brain paths.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Growth
top 35%Talent
top 38%Funding
top 44%Global
bottom 39%Tech
bottom 38%Market
bottom 27%Growth: Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $28.0M across 1 rounds · 1 rounds over 6 yrs (0.2/yr) · Last round Seed (Jan 2025)
Funding rounds
- Jan 2025Seed$28M
- Jun 2020Grant (prize money)—
Founders & team
Investors
EIT Health, Plural, Kindred Ventures, Cherry Ventures, LocalGlobe, Think.Health
Tech stack
Apple Icloud MailCloudflareGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
#7
Acquired · Saint Cloud, Ile de France · founded 1977 · 1500 employees$248.1Mraised▾
Acquired · Saint Cloud, Ile de France · founded 1977 · 1500 employees
Ethypharm is developing drugs and drug delivery systems (DDS) to treat pain and addiction. The company has developed a drug portfolio such as Morphine, Fentanyl, Tramadol, oxycodone, oxycodone hydrochloride, Etodolac-Lodine, Triamcinolone Hexacetonide, and Episil for treating pain. The company is also developing drugs for alcohol dependence, overdose, and opioid replacement.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 83k LinkedIn followers — 69.2% of this cohort's audience
Founders & team
Investors
Astorg Partners, Biovail, J P Morgan, Goldman Sachs, Economy And Finance, CDC International Capital
Tech stack
Apple Icloud MailCore-JsDocusignGsapHstsJquery
#8
Series B · Paris, Ile de France · founded 2014 · 340 employees$121Mraised▾
Series B · Paris, Ile de France · founded 2014 · 340 employees
Provider of smart healthcare solutions for sleep and EEG lab management. The company offers a comprehensive software solution that enables healthcare providers to manage sleep and EEG labs, with features such as scheduling, HST processing, and remote patient communication. Also, it offers ICECAP an EEG device for inpatient or outpatient testing.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Moat
top 19%Tech
top 25%Patents
top 29%Innovation
top 34%Funding
top 34%Market
top 45%Moat: Editorial + unicorn rating 8/10 · IP moat: 140 patents · Soonicorn
Tech: 53 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront · Devops: Nginx, Varnish
Patents: 140 patents matched (strict assignee match) · 24 filings since 2022 vs 108 in 2017-21 · Latest publication 2025
Funding rounds
- Nov 2023PE$25.6M
- Jun 2019Series B$74M
- Sep 2017Series A$18M
- Jun 2015Seed$3.4M
Investors
LBO France, Idinvest Partners, Dassault Systems, Bpifrance, Kurma Partners, Jolt Capital
Tech stack
Amazon AlbAmazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesAnimate.Css
#9
Seed · Paris, Ile de France · founded 2018 · 4 employees$1.1Mraised▾
Seed · Paris, Ile de France · founded 2018 · 4 employees
InBrain Pharma is a developer of therapeutic solutions for the treatment of neurodegenerative diseases. It has developed treatment solutions for neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, and others.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 2 awards announced in 12 mo
Funding rounds
- May 2025Seed$2M
- Mar 2019Seed$1.1M
Founders & team
Investors
Nord France Amorquage, Finovam Gestion
#10
Series B · Suresnes, Ile de France · founded 2018 · 10 employees$39.3Mraised▾
Series B · Suresnes, Ile de France · founded 2018 · 10 employees
Algo Therapeutix is a developer of therapeutic solutions for pain management. It has developed ATX01 drugs to treat the pain of chemotherapy-induced peripheral neuropathy with oral antidepressants and anti-epileptics. The medicine ATX01 helps in the pain and sensory symptoms of chemotherapy.
Funding rounds
- Mar 2023Series B$21.4M
- Nov 2020Series A$14.3M
- Nov 2019Seed$553.7K
- Jun 2018Seed$3M
Founders & team
Investors
Bpifrance, Relyens, Omnes Capital, UI Investissement
#11
Funding Raised · Paris, Ile de France · founded 2020 · 6 employees$5.3Mraised▾
Funding Raised · Paris, Ile de France · founded 2020 · 6 employees
Developer of therapeutics for the treatment of neurological and psychiatric disorders. The company's flagship product is FENM a biomarker of the brain receptor NMDA, as a treatment solution neurodegenerative diseases such as Alzheimer’s disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 1 awards announced in 12 mo
Funding rounds
- May 2024Grant (prize money)$2.7M
- 2023Grant (prize money)$2.7M
Founders & team
Investors
EIC Fund, Europa
#12
Public · Paris, Ile de France · founded 2013 · 29 employees$31.4Mraised▾
Public · Paris, Ile de France · founded 2013 · 29 employees
Developing immunotherapeutics for treating ischemic stroke. The company engages in developing therapeutic monoclonal antibodies for the treatment of ischemic strokes. It offersin developing ACT-017, a humanized antibody for the treatment of cerebral stroke and the platelet glycoprotein VI.
Funding rounds
- Nov 2019Series B$7.8M
- Oct 2018Series B$17.7M
- Jan 2018Grant (prize money)$2.6M
- Jan 2018Series B$2M
Founders & team
Investors
Primer Capital, Anaxago, Karista, Bpifrance, GO CAPITAL, Newton Biocapital
Tech stack
WebflowWeglotJqueryGoogle Hosted LibrariesGoogle Font ApiOpen Graph
Funding & investor landscape
$904.3Mtotal disclosed funding
27companies funded
73disclosed rounds
0rounds last 90 days
Most active investors
Bpifrance9 rounds
Omnes Capital3 rounds
Notable founders
Elisabeth Kogan
Co-Founder & CEO · Syremis
Rodolphe Clerval
Chief Executive Officer · Coave Therapeutics
Pierre Denys
Co-Founder · EG 427
Charles Joussain
Co-Founder · EG 427
Joana Cartocci
Co-Founder & COO · Robeauté
Bertrand Duplat
CEO · Robeauté
Aurore Gérigné
Co-founder & VP · Ethypharm
Bertrand Deluard
CEO & President · Ethypharm
Matthieu Fisichella
Co-Founder & CEO · InBrain Pharma
David Devos
Co-Founder · InBrain Pharma
Olivier Bohuon
Founder · AlgoTx
Stéphane Thiroloix
President & CEO · AlgoTx
Prism market signals · France · country-scoped Prism corpus, 1,992,126 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · France
How research on Neuroscience & Neurotech is moving in France
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,202 France-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 20% → 41% across 2008–2026.
top research entities
- Centre National de la Recherche Scientifique372
- Inserm341
- Assistance Publique – Hôpitaux de Paris141
- Centre Hospitalier Universitaire de Grenoble120
- Aix-Marseille Université119
leading researchers
Stéphan Chabardès · Christelle Baunez · Laura Cif · J. Coste · Jean‐Jacques Lemaire · Valérie Fraix · Elena Moro · Tatiana Witjas
▲
Breakthroughs230 · 19%
▲ 15%→23% share
▲1.5× share momentum7 median citations49% since 2021mostly methods-led
Breakthroughs are rising (15%→23% of field), led by Neurostimulation.
rising sub-themes (early→recent)
- Neurostimulation4→17
- Brain stimulation2→14
- Deep brain stimulation30→40
- Stimulation23→31
- Epilepsy3→10
Newly emergingHippocampal formation 0→10 · Neuroimaging 0→8 · Electrophysiology 0→7
Landmark Electronic dura mater for long-term multimodal neural interfaces · 1,049 cites
◆
Advancements588 · 49%
▼ 49%→47% share
▲1.0× share momentum9 median citations39% since 2021mostly empirical
Advancements are cooling (49%→47% of field), led by Neuromodulation.
rising sub-themes (early→recent)
- Neuromodulation10→20
- Brain stimulation4→14
- Local field potential5→15
- Thalamus7→16
- Transcranial direct-current stimulation3→11
Newly emergingProbabilistic logic 0→5
Landmark Neurostimulation for Parkinson's Disease with Early Motor Complications · 1,418 cites
▼
Concerns230 · 19%
▼ 23%→16% share
▼0.7× share momentum17 median citations34% since 2021mostly empirical
Concerns are cooling (23%→16% of field), led by Neuromodulation.
rising sub-themes (early→recent)
- Neuromodulation7→12
- Disease6→10
- Neurostimulation7→10
- Brain stimulation8→11
- Adverse effect3→4
Newly emergingCognition 0→6
Landmark Subthalamic Nucleus Stimulation in Severe Obsessive–Compulsive Disorder · 936 cites
RESEARCH HOTSPOTS · France
Where neurotech is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Paris348 · +0.40
Grenoble166 · +0.31
Marseille134 · +0.44
Lyon55 · +0.30
Toulouse16 · +0.27
Strasbourg13 · +0.48
PATENT SIGNAL · France
Who's filing neurotech patents in France
France neurotech patent filing is accelerating — 110 filings from 49 assignees (2016–2025), led by Commissariat Energie Atomique, Nextmind SAS, INST NAT Sante RECH MED; annual filings 5→23.
110 filings49 assigneespeak 23/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Commissariat Energie Atomique57
- Nextmind SAS42
- INST NAT Sante RECH MED18
- Orange10
- Vygon10
- Sorin CRM SAS9
- Centre Hospitalier UNIV Pontchai6
- UNIV Rennes6
Common questions
How many Neurology companies are there in Ile de France, France?
Radar tracks 45 indexable Neurology companies headquartered in Ile de France, France that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in Ile de France, France?
The Neurology companies in Ile de France, France on this list have raised a combined $904.3M in disclosed equity funding across 27 funded companies.
Which is the highest-funded Neurology company in Ile de France, France?
Ethypharm is the highest-funded Neurology company in Ile de France, France, with $248.1M in disclosed equity funding.
How many Neurology companies in Ile de France, France are funded?
27 of the 45 Neurology companies in Ile de France, France on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in Ile de France, France?
None of the Neurology companies in Ile de France, France on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Ile de France, France Neurology companies?
The most active investors in Ile de France, France Neurology companies on this list include Bpifrance, EIC Fund, Europa, EIT Health, Erganeo.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.